BioCrea's Anti Depression Program Voted 'Top Neuroscience Project to Watch'

BioCrea GmbH has announced that the company's NMDA NR2B NAM programme has been chosen as one of the "Top Neuroscience Projects to Watch" by Informa's IN VIVO, Start-up and The Pink Sheet. The NMDA NR2B small molecule programme is currently being developed to treat major depressive disorder (MDD) and treatment resistant depression (TRD).

BioCrea has been invited to present the project at the Therapeutic Area Partnerships (TAP) meeting, which takes place on 19–21 November 2014 in Boston, US:

Session: Track 1: Neuroscience
Presentation: Dr Tom Kronbach, CEO of BioCrea
Title: "On Target with Rapid Acting Antidepressants"
Date and Time: Thursday, 20 November 2014, 11:40 AM EST
Location: The Hyatt Regency Boston, Room: Duxbury

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees consider to be the most attractive opportunities the industry has to offer," said Marc Wortman, Editorial Director, Therapeutic Area Partnerships. "As the industry leader in strategic analysis and transaction tracking, our main goal is to give these companies exposure to potential investors, partners and acquirers."

The "Top Neuroscience Projects to Watch" have been chosen by independent industry experts. BioCrea met the selection criteria, which included an unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.

"We are complimented to be selected as one of the 'Top Neuroscience Projects to Watch' by these independent Informa experts", said Dr Tom Kronbach, CEO of BioCrea GmbH. "We very much appreciate this opportunity to discuss our NMDA NR2B NAM programme at the TAP meeting, which is one of the key neuroscience events."